🇺🇸 FDA
Patent

US 11911403

Antisense-induced exon exclusion in type VII collagen

granted A61KA61K31/70A61P

Quick answer

US patent 11911403 (Antisense-induced exon exclusion in type VII collagen) held by Sarepta Therapeutics, Inc. expires Mon Feb 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Sarepta Therapeutics, Inc.
Grant date
Tue Feb 27 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
8
CPC classes
A61K, A61K31/70, A61P, A61P17/00